China
The firm, which has also hired a senior trademark leader to lead operations in the region, believes greater China to be one of the most important IP jurisdictions
In the final part of a series on challenging patent invalidation decisions in China, lawyers at Spruson & Ferguson and Marshall Gerstein share how courts adjudicate appeals
Newly independent King & Wood has established offices in North America, while Mallesons has entered a ‘new era’ with a 1,200-lawyer firm across Australia and Singapore
In the first of a two-part article, lawyers at Spruson & Ferguson and Marshall Gerstein provide an overview of China’s system for appealing against patent invalidation decisions
Sponsored
Sponsored
-
Sponsored by Kangxin PartnersShan Xu of Kangxin Partners outlines a new provision on AI-related inventions in China’s recently revised Guidelines for Patent Examination -
Sponsored by DEQI Intellectual Property Law CorporationYanling Zhou of DEQI Intellectual Property Law Corporation explains how China’s updated rules and examination guidance for partial design patents affect filings, protection, and the assessment of design similarity and unity
-
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu and Jicheng Yang of Wanhuida Intellectual Property analyse an invalidation decision that addresses how dosage and administration features affect the inventiveness assessment of pharmaceutical use claims in China
-
Sponsored by CCPIT Patent and Trademark Law OfficeThe revised Patent Examination Guidelines foster innovation by redefining plant varieties, says Juhua Luo of CCPIT Patent and Trademark Law Office
-
Sponsored by CCPIT Patent and Trademark Law OfficeNew CNIPA examination practices on non-use cancellation raise evidentiary requirements for petitioners. Ling Zhao of CCPIT Patent and Trademark Law Office highlights the implications for registrants and enforcement strategies in China
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property explains how the CNIPA’s rulings on mirogabalin besylate tablets highlight the importance of formulation patent drafting and claim amendments in China’s drug patent landscape
